Novel Psma-Binding Agents and Uses Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a new class of small-molecule compounds that bind to prostate-specific membrane antigen (PSMA), and include an albumin-binding motif as well as a chelating group for radiolabeling. These compounds are designed to target and accumulate in PSMA-expressing tumors (notably prostate cancer), allowing for both precise imaging (diagnosis) and delivery of radiotherapeutics (treatment) to cancer cells. Enhanced pharmacokinetics allow for greater tumor uptake, longer blood circulation, and reduced off-target effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Radiopharmaceutical imaging (e.g., PET, SPECT scans) for detecting and monitoring PSMA-expressing cancers such as prostate cancer, and potentially pancreatic, renal, or bladder cancers.
• Targeted radiotherapy for treating PSMA-positive tumors through delivery of radioactive isotopes directly to cancer cells.
• Theragnostic approach, using the same compound for both diagnosis (imaging) and therapy (treatment) by varying the radiolabel.
• Monitoring treatment response and detecting cancer recurrence by non-invasive imaging.
• Potential use as a companion diagnostic in patient selection and stratification in oncology trials targeting PSMA.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific targeting of PSMA-expressing tumor cells, leading to improved imaging contrast and treatment precision.
• Addition of albumin-binding motif increases bloodstream retention of the compound, enhancing tumor delivery and reducing kidney/lacrimal/salivary gland side effects.
• Flexibility in radiolabeling: can use diagnostic or therapeutic isotopes, enabling both imaging and therapy from the same molecule/platform.
• Lower required dosing of radioactivity (reducing potential toxicity to patients and environmental burden).
• Enables earlier detection and more effective monitoring of disease progression or recurrence compared to existing techniques.
• Improved tumor-to-background signal ratios, potentially improving detection of small or early metastatic lesions.
• Optimized for clinical translation, including single-step radiolabeling and compatibility with various radionuclides.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.